Limits...
Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I - PLoS ONE (2015)

Bottom Line: Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment.Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation.These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

ABSTRACT
Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our in vitro study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT2Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

No MeSH data available.


Related in: MedlinePlus

Expression matrix of triple negative breast cancer cells after treatment with p53 siRNA, EGCG, and combined treatment.According to the bar shown below the matrix, upregulated genes are represented in red and downregulated genes are represented in green. Small black squares represent unaltered genes. Each row represents color codes for a specific gene and each column indicates the treatment strategy, which was performed in triplicate.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4388814&req=5

pone.0120936.g002: Expression matrix of triple negative breast cancer cells after treatment with p53 siRNA, EGCG, and combined treatment.According to the bar shown below the matrix, upregulated genes are represented in red and downregulated genes are represented in green. Small black squares represent unaltered genes. Each row represents color codes for a specific gene and each column indicates the treatment strategy, which was performed in triplicate.

Mentions: Using qRT-PCR array technology, we examined the transcript levels of 84 genes involved in apoptosis from the Hs578T-cell line transfected with p53 siRNA and incubated with EGCG. Relative quantification of the transcripts using the 2-ΔΔCTmethod revealed 16 genes that were upregulated and 12 genes were downregulated in response to the combined treatment of p53 siRNA cells with EGCG (Table 1 and Figs 1 and 2).


Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I - PLoS ONE (2015)

Expression matrix of triple negative breast cancer cells after treatment with p53 siRNA, EGCG, and combined treatment.According to the bar shown below the matrix, upregulated genes are represented in red and downregulated genes are represented in green. Small black squares represent unaltered genes. Each row represents color codes for a specific gene and each column indicates the treatment strategy, which was performed in triplicate.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4388814&req=5

pone.0120936.g002: Expression matrix of triple negative breast cancer cells after treatment with p53 siRNA, EGCG, and combined treatment.According to the bar shown below the matrix, upregulated genes are represented in red and downregulated genes are represented in green. Small black squares represent unaltered genes. Each row represents color codes for a specific gene and each column indicates the treatment strategy, which was performed in triplicate.
Mentions: Using qRT-PCR array technology, we examined the transcript levels of 84 genes involved in apoptosis from the Hs578T-cell line transfected with p53 siRNA and incubated with EGCG. Relative quantification of the transcripts using the 2-ΔΔCTmethod revealed 16 genes that were upregulated and 12 genes were downregulated in response to the combined treatment of p53 siRNA cells with EGCG (Table 1 and Figs 1 and 2).

Bottom Line: Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment.Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation.These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.

ABSTRACT
Triple-negative breast cancer (TNBC) is a highly aggressive phenotype that is resistant to standard therapy. Thus, the development of alternative therapeutic strategies for TNBC is essential. The purpose of our in vitro study was to evaluate the impact of p53 gene silencing in conjunction with the administration of a natural compound, epigallocatechingallate (EGCG). RT2Profiler PCR Array technology was used to evaluate the impact of dual treatment on the main genes involved in apoptosis in the Hs578T cell culture model of TNBC. Gene expression analysis revealed 28 genes were significantly altered (16 upregulated and 12 downregulated) in response to combined p53 siRNA and EGCG treatment. Further analysis revealed that p53 siRNA and EGCG dual therapy leads to the activation of pro-apoptotic genes and the inhibition of pro-survival genes, autophagy, and cell network formation. These results indicate that this dual therapy targets both the apoptotic and angiogenic pathways, which may improve treatment effectiveness for tumors resistant to conventional treatment.

No MeSH data available.


Related in: MedlinePlus